Tag Archive for inter partes review

I Called It: Kyle Bass’s First Two IPR Petitions Fail

Kyle Bass, the hedge fund manager who filed a number of inter partes review petitions against pharmaceutical companies, has struck terror into the shriveled hearts of the pharmaceutical industry. The first petitions he filed were against Acorda Therapeutics, and its stock dropped on the news. The pharmaceutical industry immediately started lobbying to change IPR procedures…

Inter Partes Review and Pharma

Here’s a video I’ve done to explain why the pharmaceutical companies’ campaign against inter partes review is disingenuous at best: You can read more about IPRs here. Note: There was a comment on Twitter pointing out that I don’t discuss Kyle Bass and his hedge fund’s attacks against some pharmaceutical patents using inter partes review.…

Three Crucial Words in Patent Reform: Inter Partes Review (Part 3)

Note: This is Part 3 in a three-part series. If you’re not comfortable with how inter partes review works, you may want to start with Part 1. If you are comfortable with IPRs, start with Part 2. Gutting Inter Partes Review Pharmaceutical and biotech companies are pushing for major changes to inter partes reviews (IPRs). First, they…